Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03696069 · ClinicalTrials.gov registry record
A Study is to Understand the Treatment Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used in the Treatment of Advanced Melanoma
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 501
- Enrollment target
NCT03696069 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 501 participants.
The verdict
NCT03696069 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 501 participants
- Enrollment target
Study Summary
The goal of the study is to understand the treatment patterns for immunotherapy agents and BRAF/MEK inhibitors used in the treatment of advanced melanoma
Interventions
- OTHER Non-Interventional
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 501 participants |
| Start Date | 2019-01-09 |
| Est. Completion | 2020-02-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03696069
The ClinicalTrials.gov registry entry for NCT03696069 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 501 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Non-Interventional is the first listed.
NCT03696069 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03696069 about?
NCT03696069 is a clinical study titled "A Study is to Understand the Treatment Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used in the Treatment of Advanced Melanoma". The goal of the study is to understand the treatment patterns for immunotherapy agents and BRAF/MEK inhibitors used in the treatment of advanced melanoma
What is the current status of trial NCT03696069?
This trial is currently completed. The enrollment target is 501 participants. The study started on 2019-01-09. Estimated completion is 2020-02-14.
What interventions are being tested in trial NCT03696069?
The interventions under investigation include: Non-Interventional (OTHER).
Who is sponsoring clinical trial NCT03696069?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.